Press Releases

Press Releases

  • April 3, 2019
    Aileron Therapeutics Completes $26M Private Placement
  • March 29, 2019
    Aileron Therapeutics Announces Pricing of $26M Private Placement
  • March 4, 2019
    Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer
  • January 16, 2019
    Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers
  • December 4, 2018
    Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting
  • November 27, 2018
    Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
  • November 7, 2018
    Aileron Therapeutics Reports Third Quarter 2018 Financial Results
  • November 5, 2018
    Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer
  • November 1, 2018
    Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
  • October 30, 2018
    Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018